[29] [30] Proper training in injection technique is essential
Continuous treatment is needed to maintain improvement in weight and health. Eli Lilly, frontrunner in commercializing GLP-1 analogs, eyes obesity treatment market Eli Lilly has long dominated the GLP-1 analog market with its diabetes treatment Trulicity (dulaglutide)
You might have heard them being referred to as GLP-1 receptor agonists or peptide weight loss drugs, because of how they work (and not to be sticklers, but technically, Mounjaro is a GLP-1/GIP receptor agonist)
So when a clinic implies a slim woman should take a GLP-1 to prevent cancer, they are well out ahead of the evidence
Eli Lilly is studying retatrutide in several phase-3 clinical trials for obesity, type-2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatosis liver disease
These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, as detailed in the Wegovy SmPC